文献速递前列腺增生与排尿功能障碍

骶神经调控三周监督测试阶段的一年随访研究

A Supervised 3 Weeks Test Phase in Sacral Neuromodulation with a 1-Year Followup.
PubMed 文献 · J Urol · 2020-07-27

这项单中心前瞻性研究纳入90例一线治疗无效的骶神经调控候选患者,在为期3周的测试阶段每周评估,失败者可行重编程。3周后56例(62%)成功;首周无应答者中42%经重编程后成为成功候选。1年随访显示早期应答者与需重编程者的成功率无显著差异(卡方检验,p=0.562)。

要点

  • 3周监督测试阶段可提高骶神经调控累积成功率
  • 首周无应答者中42%经重编程后转为成功候选
  • 需重编程者与早期应答者1年成功率无显著差异

核心结论

  • 含密切随访的3周测试阶段可提高骶神经调控累积成功率。
  • 首周无应答者经重编程后42%成为成功候选,且其1年结局与无需重编程者相当。
  • 因此强烈推荐采用监督下的3周测试阶段。

研究设计与样本

  • 患者包括膀胱过度活动症湿性48例(53%)、干性8例(9%)和非梗阻性尿潴留34例(38%)。
  • 测试阶段每周评估,失败者行重编程,第二周后可重复重编程。
  • 主要结局为3周测试阶段后及1年随访的成功率。
  • 统计采用非参数检验:数值数据用Mann-Whitney U检验,分类数据用卡方检验。

主要发现

  • 3周测试阶段后56例(62%)被认为成功。
  • 延长干预性测试提高了累积成功率。
  • 1年随访显示早期应答者与需重编程者的成功率无显著差异(卡方检验,p=0.562)。
  • 年龄(Mann-Whitney U检验,p=0.222)、性别(卡方检验,p=0.952)或适应证(卡方检验,p=0.975)方面无差异。

临床怎么用

  • 对一线治疗无效的骶神经调控候选患者,推荐采用监督下的3周测试阶段并密切随访。
  • 测试期间每周评估,对无应答者可尝试重编程,第二周后仍可重复。
  • 首周无应答不应视为失败,重编程后仍可能成功且长期结局与早期应答者相当。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We sought to determine whether prolonged interventional test phase increases cumulative success rate and compared success rates between early responders (ie within 1 week) and those in need for reprogramming (due to lack of efficacy) of sacral neuromodulation after 1-year followup. MATERIALS AND METHODS: In a single tertiary center prospective study (August 2015 to November 2018) 90 patients refractory to first line treatment were eligible for sacral neuromodulation, including 48 overactive bladder wet (53%), 8 overactive bladder dry (9%) and 34 nonobstructive urinary retention (38%). Patients were evaluated at weekly intervals during test phase and those not successful were reprogrammed. This could be repeated after the second week. Primary outcome was success rate after 3-week test phase and after 1-year followup. Statistical analysis was done by nonparametric tests for numeric (Mann-Whitney U) and categorical (chi2) data. RESULTS: After 3 weeks of test period 56 patients (62%) were considered successful. Prolonged interventional testing increased cumulative success. A 1-year followup showed no significant difference in success rate between early responders and those in need for reprogramming (chi2, p=0.562). There was no difference in age (Mann-Whitney U, p=0.222), sex (chi2, p=0.952) or indication (chi2, p= 0.975). CONCLUSIONS: A 3-week test phase with close followup increases cumulative success rate. During this supervised 3-week test phase 42% of the initial nonresponders after the first week became successful candidates after reprogramming. Patients who required this additional programming did equally as well as those without need for reprogramming. A supervised 3-week test phase is therefore strongly recommended.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Tilborghs S, Van de Borne S, Vaganée D, et al. A Supervised 3 Weeks Test Phase in Sacral Neuromodulation with a 1-Year Followup. J Urol. 2020. PMID: 32716692. doi:10.1097/JU.0000000000001317

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。